{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:47:18Z","timestamp":1774928838085,"version":"3.50.1"},"reference-count":30,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"crossref","award":["TSGH-D113076"],"award-info":[{"award-number":["TSGH-D113076"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"crossref","award":["TSGH-D114168"],"award-info":[{"award-number":["TSGH-D114168"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: The benefit of adjuvant chemotherapy for low-risk, mismatch repair proficient (pMMR) stage IIA colon cancer is uncertain. Surveillance is standard, but some patients relapse. Tegafur-uracil (UFT) is a low-toxicity oral option that may offer benefit; Methods: This retrospective study included patients with resected low-risk, pMMR stage IIA colon cancer (2013\u20132022). Patients receiving \u22655 postoperative UFT prescriptions were compared with those under surveillance. Propensity score matching (1:1) was applied, and disease-free survival (DFS) and overall survival (OS) were analyzed using Kaplan\u2013Meier and Cox models with sensitivity analyses.; Results: Among 279 eligible patients, 71 matched pairs were analyzed. UFT reduced the risk of recurrence or death by 57% (DFS HR = 0.43, 95% CI 0.25\u20130.75, p = 0.002) and mortality by 62% (OS HR = 0.38, 95% CI 0.21\u20130.68, p &lt; 0.001); Conclusions: UFT improved DFS and OS in low-risk pMMR stage IIA colon cancer, suggesting surveillance alone may undertreat some patients. Prospective trials are warranted.<\/jats:p>","DOI":"10.3390\/life15121930","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:13:03Z","timestamp":1765973583000},"page":"1930","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvant Tegafur-Uracil Improves Survival in Low-Risk, Mismatch Repair Proficient Stage IIA Colon Cancer: A Propensity Score-Matched Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8529-1875","authenticated-orcid":false,"given":"Min-Chi","family":"Cheng","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"},{"name":"Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-945X","authenticated-orcid":false,"given":"Hsu-Lin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"},{"name":"Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"},{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Taichung Armed Forces General Hospital, Taichung 404313, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiue-Wei","family":"Lai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"},{"name":"Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"},{"name":"Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0280-6417","authenticated-orcid":false,"given":"Po-Huang","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"},{"name":"Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei 11490, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100184","DOI":"10.1016\/j.esmoop.2021.100184","article-title":"How I Treat Stage II Colon Cancer Patients","volume":"6","author":"Taieb","year":"2021","journal-title":"ESMO Open"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1200\/JCO.21.02538","article-title":"Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update","volume":"40","author":"Baxter","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.22.02462","article-title":"Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline","volume":"41","author":"Vikas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.5858\/arpa.2021-0632-CP","article-title":"Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline from the College of American Pathologists in Collaboration with the Association for Molecular Pathology and Fight Colorectal Cancer","volume":"146","author":"Bartley","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1007\/s00464-024-10723-z","article-title":"Survival Paradox between Stage IIB\/C and Stage IIIA Colon Cancer: Is It Time to Revise the American Joint Committee on Cancer TNM System?","volume":"38","author":"Chu","year":"2024","journal-title":"Surg. Endosc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4088117","DOI":"10.1155\/2022\/4088117","article-title":"Survival Contradiction in Stage II, IIIA, And IIIB Colon Cancer: A Surveillance, Epidemiology, and End Result-Based Analysis","volume":"2022","author":"Li","year":"2022","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.21873\/anticanres.17726","article-title":"Tegafur-Uracil as a Maintenance Therapy for Non-Metastatic Nasopharyngeal Carcinoma: Insights from the Literature","volume":"45","author":"Yang","year":"2025","journal-title":"Anticancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lee, H.-L., Chen, P.-H., Huang, T.-C., Ye, R.-H., Chu, Y.-H., Lee, J.-C., Jhou, H.-J., and Chen, J.-H. (2025). Tegafur-Uracil Maintenance Therapy in Non-Metastatic Head and Neck Cancer: An Exploratory Systematic Review. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32050286"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e25756","DOI":"10.1097\/MD.0000000000025756","article-title":"Uracil-Tegafur vs Fluorouracil as Postoperative Adjuvant Chemotherapy in Stage II and III Colon Cancer","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Chen, P.-H., Jhou, H.-J., Chung, C.-H., Wu, Y.-Y., Huang, T.-C., Lee, C.-H., Chien, W.-C., and Chen, J.-H. (2022). Benefit of Uracil-Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer. Medicina, 59.","DOI":"10.3390\/medicina59010010"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/jjco\/hyu211","article-title":"Quality assessment and improvement of nationwide cancer registration system in Taiwan: A review","volume":"45","author":"Chiang","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jfma.2021.04.022","article-title":"Accuracy of long-form data in the Taiwan cancer registry","volume":"120","author":"Kao","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jfma.2019.01.012","article-title":"Taiwan\u2019s Nationwide Cancer Registry System of 40 years: Past, present, and future","volume":"118","author":"Chiang","year":"2019","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Yang, Z.-Y., Chen, W.-L., Wu, W.-T., and Wang, C.-C. (2022). Return to Work and Mortality in Breast Cancer Survivors: An 11-Year Longitudinal Study. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph192114418"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 Version of the Charlson Comorbidity Index Predicted in-Hospital Mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J. Clin. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/psp4.13014","article-title":"Can a Propensity Score Matching Method Be Applied to Assessing Efficacy from Single-Arm Proof-of-Concept Trials in Oncology?","volume":"12","author":"Teng","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jclinepi.2023.09.014","article-title":"The Use of the E-Value for Sensitivity Analysis","volume":"163","author":"Chung","year":"2023","journal-title":"J. Clin. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/0284186X.2014.975839","article-title":"Risk of Recurrence in Patients with Colon Cancer Stage II and III: A Systematic Review and Meta-Analysis of Recent Literature","volume":"54","author":"Engelmann","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejca.2018.03.009","article-title":"A Randomised-Controlled Trial of 1-Year Adjuvant Chemotherapy with Oral Tegafur-Uracil Versus Surgery Alone in Stage II Colon Cancer: SACURA Trial","volume":"96","author":"Matsuda","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1200\/JCO.18.02059","article-title":"Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results from the SACURA Trial","volume":"37","author":"Ueno","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rebuzzi, S.E., Pesola, G., Martelli, V., and Sobrero, A.F. (2020). Adjuvant Chemotherapy for Stage II Colon Cancer. Cancers, 12.","DOI":"10.3390\/cancers12092584"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","article-title":"Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer","volume":"349","author":"Ribic","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12935-025-03807-w","article-title":"UFUR Maintenance Therapy Significantly Improves Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Chemoradiotherapy","volume":"25","author":"Hsieh","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4174\/astr.2022.102.5.271","article-title":"Effectiveness of Oral Fluoropyrimidine Monotherapy as Adjuvant Chemotherapy for High-Risk Stage II Colon Cancer","volume":"102","author":"Cho","year":"2022","journal-title":"Ann. Surg. Treat. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sadahiro, S., Sakamoto, K., Tsuchiya, T., Takahashi, T., Ohge, H., Sato, T., Kondo, K., Ogata, Y., Baba, H., and Itabashi, M. (2022). Prospective Observational Study of the Efficacy of Oral Uracil and Tegafur plus Leucovorin for Stage II Colon Cancer with Risk Factors for Recurrence Using Propensity Score Matching (JFMC46-1201). BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09267-z"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10147-024-02565-5","article-title":"Final Analyses of the Prospective Controlled Trial on the Efficacy of Uracil\u2013Tegafur\/Leucovorin as Adjuvant Treatment for Stage II Colon Cancer with Risk Factors for Recurrence Using Propensity Score-Based Methods (JFMC46-1201)","volume":"29","author":"Ogata","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yu, Y.-L., Tseng, W.-K., Liao, C.-K., Yeh, C.-Y., Chen, H.-H., Liu, Y.-H., and Lin, T.-L. (2023). Using Oral Tegafur\/Uracil (UFT) Plus Leucovorin as Adjuvant Chemotherapy in Stage II Colorectal Cancer: A Propensity Score Matching Study from Taiwan. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11310-6"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e000366","DOI":"10.1136\/bmjmed-2022-000366","article-title":"Quantifying the Impact of Unmeasured Confounding in Observational Studies with the E Value","volume":"2","author":"Gaster","year":"2023","journal-title":"BMJ Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"104072","DOI":"10.1016\/j.esmoop.2024.104072","article-title":"The Clinical Dilemma of High-Risk Stage II Colon Cancer: Are We Truly Prepared to Withdraw Oxaliplatin?","volume":"9","author":"Taieb","year":"2024","journal-title":"ESMO Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"31","author":"Tabernero","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/12\/1930\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:12:23Z","timestamp":1766121143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/12\/1930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["life15121930"],"URL":"https:\/\/doi.org\/10.3390\/life15121930","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}